CV

Univ. Prof. Dr. rer. nat. Stefan Knapp

Academic education

1987 - 1990: Chemistry, University of Marburg, Germany and University of Illinois, USA

Scientific degrees

1992: Diploma (Chemistry) Mentor: Prof M. Beato (Marburg)
1992 - 1996: PhD thesis, Karolinska Institute, Stockholm, Sweden, Mentor: Prof. Dr. R. Ladenstein

Scientific career

2017 - present: CSO of the Structural Genomics Consortium site at Frankfurt University
2015 - present: Professor for Pharmaceutical Chemistry (W3), GU, Frankfurt, Germany
2012 - 2015: Director of Chemical Biology, Target Discovery Institute (TDI), Nuffield Department of Clinical Medicine, University of Oxford, UK
2008 - 2015: Professor of Structural Biology, Nuffield Department of Clinical Medicine, University of Oxford, UK
2004 - present: Principal Investigator, Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, UK
1999 - 2004: Principal Scientists, Chemistry and Structural Biology, Pharmacia Corp. Nerviano, Italy
1996 - 1999: Postdoctoral Fellow, Karolinska Institute, Stockholm, Sweden

Honors/ Awards/ Memberships

2018: Elected member of EMBO Society
2017: Biochemical Society Award
2014: Rita and John Cornforth Award of the Royal Society of Chemistry
2012: Fellow of the American Chemical Society
1997: Boehringer Ingelheim Fellowship
2012 - present: Member of the American Chemical Society

10 most relevant publications

  • Ciceri P, Muller S, O'Mahony A, Fedorov O, Filippakopoulos P, Hunt JP, Lasater EA, Pallares G, Picaud S, Wells C, Martin S, Wodicka LM, Shah NP, Treiber DK & Knapp S. Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat Chem Biol, 2014 Apr;10(4):305-12.
  • Chaikuad AE, Zimmer J, Liang Y, Gray NS, Tarsounas M, Knapp S. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nat Chem Biol2014 Oct;10(10):853-60.
  • Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Gokturk C, Sanjiv K, Stromberg K, Pham T, Berglund UW, Colinge J, Bennett KL, Loizou JI, Helleday T, Knapp S & Superti-Furga G. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014 Apr 10;508(7495):222-7.
  • Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, Fedorov O, Brennan P, Bunnage ME, Owen DR, Bradner JE, Taniere P, O'Sullivan B, Muller S, Schwaller J, Stankovic T & Knapp S. PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains. Cancer Res, 2013 Jun 1;73(11):3336-46.
  • Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, Felletar I, Volkmer R, Muller S, Pawson T, Gingras AC, Arrowsmith CH & Knapp S. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell, 2012 Mar 30;149(1):214-31.
  • Matzuk MM, McKeown MR, Filippakopoulos P, Li Q, Ma L, Agno JE, Lemieux ME, Picaud S, Yu RN, Qi J, Knapp S& Bradner JE. Small-Molecule Inhibition of BRDT for Male ContraceptionCell, 2012 Aug 17;150(4):673-84.
  • Deutsch GB, Zielonka EM, Coutandin D, Weber TA, Schäfer B, Hannewald J, Luh LM, Durst FG, Ibrahim M, Hoffmann J, Niesen FH, Sentürk A, Kunkel H, Brutschy B, Schleiff E, Knapp S, Acker-Palmer A, Grez M, McKeon F, Dötsch V. DNA damage in oocytes induces an irreversible switch of the quality control factor TAp63 delta from dimer to tetramer. Cell, 2011 Feb 18;144(4):566-76.
  • Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, French CA, Wiest O, Kung AL, Knapp S* & Bradner JE*. Selective inhibition of BET bromodomains. Nature, 2010 Dec 23;468(7327):1067-73. *co-corresponding authors
  • Barr AJ, Ugochukwu E, Lee WH, King ON, Filippakopoulos P, Alfano I, Savitsky P, Burgess-Brown NA, Muller S & Knapp S. Large-scale structural analysis of the classical human protein tyrosine phosphatomeCell, 2009 Jan 23;136(2):352-63.
  • Filippakopoulos P, Kofler M, Hantschel O, Gish GD, Grebien F, Salah E, Neudecker P, Kay LE, Turk BE, Superti-Furga G, Pawson T & Knapp S. Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell, 2008 Sep 5;134(5):793-803

Patents

  • 2003: Interaction inhibitors of Tcf-4 with beta-catenin. WO03006447, WO2003006447 A220030123
  • 2003: Truncated human dbf4 in complex with its interacting partners (catalytic subunits) such as human cdc7, and methods for the production of monodisperse heterodimers for identification and optimization of inhibitors thereof. WO/2004/099243

Contact Information

Univ. Prof. Dr. rer. nat. Stefan Knapp SFB1399
Univ. Prof. Dr. rer. nat. Stefan Knapp

Professor of Pharmaceutical Chemistry (W3) and site head SGC (Structural Genomics Consortium Frankfurt)

Goethe-Universität Frankfurt

Institute for Pharmaceutical Chemistry

Curriculum Vitae (CV)

CV